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Synthesis of UCNPs@SiO 2 . According to an O/W reverse microemulsion method, 1 mL of Igepal CO-520 (NP-5) was dispersed in 20 mL cyclohexane. Afterwards, oleic acid capped UCNPs in cyclohexane solution (1.5 mL, 100 mM) was added into the cyclohexane/NP-5 mixture. After magnetic stirring for 3 h, 140 µL ammonia (30%) was added dropwise, and the system was stirred for 2 h. Then 130 µL tetraethyl orthosilicate (TEOS) was injected into the system through a syringe pump (WZS-50F6) at a rate of 130 µL/h. The mixture was sealed and kept stirring for 36 h before adding methanol to terminate reaction. The resulting UCNPs@SiO 2 products were washed with ethanol and cyclohexane several times to remove excess NP-5, and finally dispersed in 5 mL deionized water.
Synthesis of UCNPs@SiO 2 @mSiO 2 . Cetyltrimethylammonium chloride (CTAC) was used as poreforming agents as well as surfactant agents for the coating of mesoporous silica on as-synthesized UCNPs@SiO 2 . CTAC (2 g) and TEA (0.02 g) were mixed in 20 mL deionized water under intense stirring for 1.5 h. Then UCNPs@SiO 2 in 10 mL deionized water was added and kept stirring for another 1.5 h. Afterwards, 200 µL tetraethyl orthosilicate (TEOS) was added dropwize and the system was stirred at 80 ℃ for 1 h. The resulting UCNPs@SiO 2 @mSiO 2 products were washed with ethanol several times and extracted with NaCl in 30 mL methanol (1 wt %) for 3 h at room temperature to remove the template CTAC. The extraction was carried out several times and the final UCNPs@SiO 2 @mSiO 2 products were dispersed in 10 mL deionized water.
Synthesis of ligand-free UCNPs. 2.5 mL cyclohexane of UCNPs (100 mM) was added into 10 mL deionized water, followed by injecting 20 μL HCl (37 wt%). After kept stirring for 2 h, almost all UCNP nanoparticles were transferred from cyclohexane to water. Then the products were centrifuged and washed by water three times, and finally dispersed in 15 mL deionized water.
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Synthesis of UCNPs@mSiO 2 . Cetyltrimethylammonium chloride (CTAC) was used as pore-forming agents for the coating of mesoporous silica on as-synthesized ligand-free UCNPs. CTAC (2 g) and TEA (0.02 g) were mixed in 20 mL deionized water under intense stirring for 1 h. Then ligand-free UCNPs in 15 mL deionized water was added, and kept sonicating for another 1.5 h. Afterwards, 200 µL tetraethyl orthosilicate (TEOS) was added dropwize and the system was stirred at 80 ℃ for 1 h. The resulting UCNPs@mSiO 2 products were washed with ethanol several times and extracted with NaCl in 30 mL methanol (1 wt %) for 3 h at room temperature to remove the template CTAC. The extraction was carried out several times and the final UCNPs@mSiO 2 products were dispersed in 10 mL deionized water.
Synthesis of RUMSNs.
According to the "surface-protected hot water etching" method, as-prepared UCNPs@mSiO 2 or UCNPs@SiO 2 @mSiO 2 in 10 mL deionized water was added into a 50 mL flask containing 10 mL deionized water of PVP (0.25 g, Mw = 40000). The mixture was stirred for 0.5 h, and then heated to 95 ℃. After etching for 4 h, the system was then cooled down to the room temperature.
The resulting RUMSNs products were washed with ethanol and water several times, and finally dispersed in 10 mL deionized water.
Synthesis of RUMSNs-TAT.
To make TAT peptide (nuclear targeting peptide) grafted onto the surface of RUMSNs, TAT was first let to react with APTES to form the amino-functionalized TAT silane precursor. In a typical procedure, TAT (0.2 mmol), EDC (38 mg) and NHS (57 mg) were dissolved in 8 mL deionized water followed by addition of 45 µL APTES. The system was stirred for 24 h at room temperature to produce amino-functionalized TAT silane precursor. Then 10 mg RUMSNs in 5 ml deionized water was added and the system was further stirred for 24 h. The final TAT-grafted RUMSNs (RUMSNs-TAT) nanoparticles were collected by centrifugation, washed with water several times, and finally dispersed in 5 ml deionized water for further use.
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In vitro toxicity assessment of RUMSNs/RUMSNs-TAT. MCF-7 or MCF-7/ADR cells were seeded into a 96-well plate at 10 4 /well and then cultured at 37℃ under 5% CO 2 for 24 h. Different concentrations (7.5, 15, 31.5, 62.5, 125, 250 , 500 and 1000 µg/mL) of RUMSNs/RUMSNs-TAT in the culture media (DMEM) were added into the wells and co-incubated for 24 h/48 h at 37 ℃ under 5% CO 2 . Cell culture supernatants were then harvested and assayed for lactate dehydrogenase (LDH) activity using the LDH release assay kit (Beyotime). Released LDH was expressed as a percentage of maximum LDH release induced by the incubation of cells with 1% Triton X-100, after normalization to cells treated with corresponding formulations. Meanwhile, the treated cells were further incubated with 100 μL fresh medium containing 10 μL Cell Counting Kit-8 (CCK-8) solutions for additional 4 h. Then the absorbance of each well was monitored by a microplate reader at the wavelength of 450 nm. The cytotoxicity was finally expressed as the percentage of cell viability in contrast to untreated control cells.
Intracellular localization profile of RUMSNs and RUMSNs-TAT by confocal laser scanning microscopic (CLSM) imaging. MCF-7 or MCF-7/ADR cells were seeded and cultured into a CLSMspecial cell culture dish at 37 ℃ under 5% CO 2 . After the cell density reached 50~60%, 1 mL DMEM solutions of RUMSNs/RUMSNs-TAT (400 µg/mL) were added into the culture dish. After co-incubation for 24 h, the cells were washed three times with PBS to remove free RUMSNs/RUMSNs-TAT, followed by nuclei staining by DAPI. Confocal luminescence imaging experiments were carried out on an Olympus FV1000 laser-scanning microscope equipped with a CW NIR laser (λ = 980 nm) as the excitation source. A 60×oil immersion objective lens was used and visible luminescence signals were detected in the wavelength regions of 500~560 nm and 620~680 nm, respectively. Three dimensional luminescence reconstruction of nanoparticle-endocytosized cells were conducted by serial layer scanning of cells along Z-axis and 3-D reconstruction of scanned luminescence images.
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Intracellular localization profile of RUMSNs and RUMSNs-TAT by bio-TEM observations. MCF-7 or MCF-7/ADR cells were incubated with 400 µg/mL DMEM solutions of RUMSNs and RUMSNs-TAT for 24 h. Then, the cells were washed twice with D-hanks and detached by incubation with 0.25% trypsin for 5 min. The cell suspension was centrifuged at 3000 r/min for 3 min. After the removal of incubation medium, the cells were fixed by glutaraldehyde at room temperature, rinsed with PBS, ehydrated through a graded ethanol series, and finally cleared with propylene oxide. Then, the cell sample was embedded in EPOM812 and polymerized in an oven at 37 ℃ for 12 h, 45 ℃ for 12 h and 60 ℃ for 48 h. Ultrathin sections of approximately 70 nm in thickness were cut with a diamond knife on a Leica UC6 ultramicrotome and transferred to the copper grid.
In vitro evaluation of intranuclear radiosensitization. MCF-7 or MCF-7/ADR cells were seeded into several 6-well plates at a density of 10 5 cells per well and then cultured for 24 h at 37℃ under 5% CO 2 .
The cells were divided into eight groups: control, MMC, RUMSNs-MMC, RUMSNs-TAT-MMC, radiation, MMC + radiation, RUMSNs-MMC + radiation, RUMSNs-TAT-MMC + radiation. Briefly, 1 mL DMEM solutions of MMC/RUMSNs-MMC/RUMSNs-TAT-MMC ([MMC]= 0.5 µg/mL or 10 µg/mL) were added into the plates and co-incubated for another 24 h, respectively. Then the cells were exposed to 5 Gy X-ray irradiation for 5 min, and then continuously cultured for another 24 h and 48 h.
Finally, the living cells of each group were counted. Measurement of intracellular reactive oxygen species. The intracellular ROS level was measured using an oxidation sensitive fluorescent probe (DCFH-DA) (Beyotime, Shanghai, China). DCFH-DA can be deacetylated by nonspecific esterase to form DCFH, which can be oxidized by hydrogen peroxide or lowmolecular-weight peroxides to produce a stable fluorescent ROS-sensitive compound 2, 7-dichlorofluorescein (DCF). In this study, MCF-7 or MCF-7/ADR cells were seeded at a density of
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MMC/RUMSNs-TAT-MMC for another 24 h. After imposing 5 Gy X-ray irradiation, the cells were harvested and washed with serum-free medium 3 times. Then the aliquots of cells were re-suspended in fresh medium without serum and incubated with DCFH-DA (30 μM) for 20 min at 37℃. Finally, Green luminescence density of 10,000 events for each sample was detected by flow cytometry.
Analysis of apoptosis.
Briefly, MCF-7 or MCF-7/ADR cells were seeded at a density of 10 5 /well. After 24 h of incubation, the corresponding cells were treated with MMC/RUMSNs-MMC/RUMSNs-TAT-MMC for another 24 h. After imposing 5 Gy X-ray irradiation, the cells were further incubated for 24 h. 
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were purchased from Laboratory animal center, shanghai medical college of Fudan University. Human breast cancer line MCF-7 cells (5×10 6 cell/site) were implanted subcutaneously into balb/c nude mice.
Magnetic resonance imaging studies were performed when the tumor reached 10 mm in average diameter.
In vivo MRI test was conducted at a 3.0 T clinical MRI instrument after intravenous injection of RUMSNs/RUMSNs-TAT (10 mg/ml, 150 µL). The MRI image and the corresponding MRI signal intensity were obtained 5 min/15 min post-injection.
In vivo synergetic therapy experiments on MCF-7 tumors. Human breast cancer line MCF-7 cells (5×10 6 cell/site) were implanted subcutaneously into female balb/c nude mice (~20 g). In vivo synergetic therapy experiments were performed when the tumor reached 6~8 mm in average diameter (10 days after implant). The mice were divided into six groups and each group included six mice. The first group of mice received physiological saline, as control group; the second group received MMC loaded RUMSNs (20 mg/mL, 150 µL) in physiological saline, as RUMSNs-MMC group; the third group received MMC loaded RUMSNs-TAT (20 mg/mL, 150 µL) in physiological saline, as RUMSNs-TAT-MMC group; the fourth group was subject to X-ray (dose = 8 Gy, t = 5 min) irradiation, as RT group; the fifth group was subject to X-ray (dose = 8 Gy, t = 5 min) irradiation after intravenous injection of MMC loaded RUMSNs (20 mg/mL, 150 µL) in physiological saline, as RUMSNs-MMC + RT group; the sixth group was subject to X-ray (dose = 8 Gy, t = 5 min) irradiation after intravenous injection of MMC loaded RUMSNs-TAT (20 mg/mL, 150 µL) in physiological saline, as RUMSNs-TAT-MMC + RT group. During the next two weeks after the corresponding treatments, the volume of tumors was measured every other day.
To further evaluate the treatment efficiency of each group, the tumors were dissected three days after the corresponding therapies and fixed in 10% formaldehyde. Then the tumors were sectioned into slices and H&E stained for histology studies.
In vivo synergetic therapy experiments on MCF-7/ADR tumors. Multi-drug resistant human breast cancer line MCF-7/ADR cells (5×10 6 cell/site) were implanted subcutaneously into female balb/c nude S9 mice (~20 g). In vivo synergetic therapy experiments were performed when the tumor reached 6~8 mm in average diameter (20 days after implant). The mice were divided into two groups and each group included six mice. The first group of mice received physiological saline, as control group; the second group was subject to X-ray (dose = 8 Gy, t = 5 min) irradiation after intravenous injection of MMC loaded RUMSNs-TAT (20 mg/mL, 150 µL) in physiological saline, as RUMSNs-TAT-MMC + RT group.
During the next two weeks after the corresponding treatments, the volume of tumors was measured every other day. Three days after the corresponding therapies, the tumors were dissected and fixed in 10%
formaldehyde. Then the tumors were sectioned into slices and H&E stained for histology studies. The corresponding relaxivity value of RUMSNs is estimated to be r 1 = 1.17 mM -1 s -1 . For example in Figure 4a at 0.5 μg/mL of MMC used, by the calculation according to the above equation, the corresponding radiation enhancement rates of MMC, RUMSNs-MMC, and RUMSNs-TAT-MMC are estimated to be about 0, 0.8%, and 4.6%, respectively, which means the negligible radiosensitizing effect of such low concentration of free MMC. As a matter of fact, in this case only 0.5 μg/mL of MMC was used in the experiments and very limited amount of MMC could be uptaken into the cells for enhanced RT, so the radiosensitizing effect of free MMC was negligible in the present case. Comparatively, RUMSNs-MMC and RUMSNs-TAT-MMC demonstrated substantially enhanced radiation enhancement efficiency because much more MMC could be efficiently delivered into the cytoplasm and even the nucleus for greatly improving the RT effects. Therefore, the above result clearly shows the superior advantages of our designed nuclear-targeting nanotheranostics in elevating radiation enhancement efficiency via delivering the radiosensitive drugs into cell nucleus. In Figure 4b , the radiation enhancement rates of high concentration (10 μg/mL) of MMC, RUMSNs-MMC and RUMSNs-TAT-MMC are roughly estimated to be 10.7%, 13.1%, and 20.3%, respectively, which demonstrates much stronger radiosensitizing effects due to the relatively high concentration of drugs used. All the above analysis confirms the radiosensitization of MMC and higher chemo-drug sensitized radiation enhancement efficiency of the nuclear-targeting nanotheranostics based on intranuclear radiosensitization.
